BCAB - CIK 0001826892
The table below shows BioAtla, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $4.58M | $9.54M | $13.68M | $12.36M | $16.39M | $16.20M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.73M |
| $4.25M |
| $4.96M |
| $5.26M |
| $5.88M |
| $5.77M |
| Operating income | -$9.31M | -$13.79M | -$18.65M | -$17.61M | -$11.27M | -$21.97M |
| Income tax | - | - | - | - | - | - |
| Net income | -$6.34M | -$15.78M | -$18.71M | -$15.33M | -$10.59M | -$21.07M |
| EPS (diluted) | -$4.22 | -$0.27 | -$0.32 | -$13.16 | -$0.22 | -$0.44 |